Tiepeng Li
-
- Cancer Immunotherapy and Biomarkers 19
- CAR-T cell therapy research 11
- Peptidase Inhibition and Analysis 4
- Cancer Cells and Metastasis 3
-
- Immune Cell Function and Interaction 10
- Immunotherapy and Immune Responses 5
-
- Renal cell carcinoma treatment 3
-
- RNA modifications and cancer 3
- Cited by
- OncologyImmunologyCancer Research
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Tiepeng Li
34 papers receiving 425 citations
Peers
Comparison fields: 5 of 72
- Oncology 219
- Immunology 129
- Cancer Research 85
- Aging 9
- Geriatrics and Gerontology 16
Countries citing papers authored by Tiepeng Li
This map shows the geographic impact of Tiepeng Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tiepeng Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tiepeng Li more than expected).
Fields of papers citing papers by Tiepeng Li
This network shows the impact of papers produced by Tiepeng Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tiepeng Li. The network helps show where Tiepeng Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Tiepeng Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 4 | |
| 5 | 2024 | 6 | |
| 6 | 2024 | 1 | |
| 7 | 2023 | 12 | |
| 8 | 2023 | 9 | |
| 9 | 2022 | 9 | |
| 10 | 2022 | 9 | |
| 11 | 2022 | 4 | |
| 12 | 2022 | 12 | |
| 13 | 2022 | 60 | |
| 14 | 2021 | 0 | |
| 15 | 2021 | 4 | |
| 16 | 2020 | 3 | |
| 17 | 2019 | 6 | |
| 18 | 2018 | 25 | |
| 19 | 2018 | 21 | |
| 20 | 2013 | 16 |
About Tiepeng Li
Tiepeng Li is a scholar working on Oncology, Immunology and Aging, having authored 37 papers that have together received 428 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (19 papers), CAR-T cell therapy research (11 papers), Immune Cell Function and Interaction (10 papers), Immunotherapy and Immune Responses (5 papers), Peptidase Inhibition and Analysis (4 papers), Renal cell carcinoma treatment (3 papers), Cancer Cells and Metastasis (3 papers) and RNA modifications and cancer (3 papers). The work is most often cited by research in Oncology (219 citations), Immunology (129 citations) and Cancer Research (85 citations). Tiepeng Li has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Quanli Gao, Lingdi Zhao, Peng Qin, Yonghao Yang, Lu Han, Benling Xu, Long Yuan, Weijia Fang, Kangdong Liu and Ning Huang.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.